Effectiveness of administration of bronchodilator by spacers, home-made spacers and nebulizers in patients with chronic obstructive pulmonary disease

Andrean Lesmana, Amira Permatasari Tarigan, Fajrinur Syarani


Background: In chronic obstructive pulmonary disease (COPD), bronchodilator therapy using dry powder inhaler (DPI) or a measured dose inhaler (MDI) is more convenient at a lower cost than nebulizer therapy. Mistakes in the use of MDI often occur due to lack of coordination but with the addition of spacers, drawbacks in the use of this MDI can be overcome so that it does not require coordination. Commercial spacers are relatively expensive and not available anywhere while home-made spacers made from bottles of mineral water are very cheap and can be made alone. Study aimed to evaluate the effectiveness of each device, namely a spacer, a home-made spacer and nebulizer.

Methods: This study is an experimental study of 62 COPD patients who received bronchodilators using spacers, home-made spacers, and nebulizers. Spirometry is performed for each sample before and after bronchodilator administration to assess FEV1, KVP and changes in VAS dyspnea. The difference in the effectiveness of bronchodilators for various devices in COPD patients was statistically analyzed using the ANOVA test.

Results: There were significant differences in the values of VEP1, KVP and VAS dyspnoea after bronchodilator administration through the spacer, home-made spacer and nebulizer (p<0.001), (p=0.002), (p<0.001). The increase in% VEP1 with a nebulizer device was higher than that of a spacer (p=0.001) and the increase in% VEP1 with the nebulizer device was also significantly significant compared to home-made spacer (p<0.001). The increase in% KVP with the nebulizer device was higher than that of home-made spacer (p<0.001), as well as between spacers and home-made spacers and this was significant (p=0.038). The decrease in VAS dyspnoea in patients using nebulizer device than the spacer (p<0.001). Decreasing VAS dyspnoea with nebulizer devices is higher compared to home-made spacers, also gives significant results (p<0.001). There were no differences in the decrease in VAS dyspnoea between spacers and home-made spacers.

Conclusions: The administration of bronchodilators by use of three devices (spacers, home-made spacers and nebulizers) can significantly increase the values of FEV1, KVP and VAS dyspnoea. On the use of spacers and home-made spacers, the increase of pulmonary physiological values is not significantly different.


COPD, Home-made spacers, Nebulizers, Spacers

Full Text:



Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respirat Critic Care Med. 2017;195(5):557-82.

Ramlal SK, Visser FJ, Hop WC, Dekhuijzen PN, Heijdra YF. The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters. Respirat Med. 2013;107(9):1393-9.

Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respirat Med. 2007;101:2395-401.

Alamoudi OS. Pitfalls of inhalation technique in chronic asthmatics. Effect of education program and correlation with peak expiratory flow. Saudi Med J. 2003;24(11):1205-9.

Panicker J, Sethi GR, Sehgal V. Comparative Efficiency of Commercial and Improvised Spacer Device in Acute Bronchial Asthma. Indian Pediatr. 2001;38:340-8.

Noseda A, Schmerber J, Prigogine T, Yernault JC. Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J. 1992;5:1043-53.

Tarigan AP. Hubungan Polimorfisme Gen TNF╬▒ Pada Posisi -308 Dan -238 With the incidence of chronic obstructive pulmonary disease. Univ North Sumatra. 2013.

Ran PX, Wang C, Yao WZ, Chen P, Kang J, Huang SG, et al. A study on the correlation of body mass index with chronic obstructive pulmonary disease and quality of life. Chin J Tubercul Resp Dis. 2007;30(1):18-22.

Yerbury P, Bains P, Selvan VA. Pharmacological Management in Symptom Management. In: Blackler L, Jones C, Mooney C, eds. Managing chronic obstructive pulmonary disease. England: John Wiley & Sons Ltd; 2007:27-38.

Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. Am Fam Physic. 2011;84(1).

Chong Neto HJ, Chong-Silva DC, Marani DM, Kuroda F, Olandosky M, Noronha LD. Different inhaler devices in acute asthma attacks: a randomized, double-blind, placebo-controlled study. J Pediatr. 2005;81(4):298-304.

Poole PJ, Saini R, Brodie SM, Black PN. Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD. Resp Med. 2005;99(3):372-6.

Taffet GE, Donohue JF, Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clinic Int Aging. 2014;9:23.

Hajian B, De Backer J, Vos W, Aerts J, Cluckers J, De Backer W. Efficacy of inhaled medications in asthma and COPD related to disease severity. Expert Opinion Drug Deliv. 2016;13(12):1719-27.